Evotec Investor Presentation Deck

evotec A BAYER 2016/17 • Upfront ● • Research funding • Milestones > € 300 m per product • Tiered royalties PAGE 15 E.MPD core component of alliances in CKD CKD strategic drug discovery deals V VIFOR PHARMA 2018/19 • Vifor funded: € 25 m • 50% on all projects • JV: NepThera Neph Thera novo nordisk 2020 Ⓡ Upfront • Research funding • Milestones > € 150 m per product • Tiered royalties Pending acquisition by CSL Limited not closed, yet CHINOOK THERAPEUTICS 2021 Upfront • Research funding From Target identification & validation, via biomarker identification, to patient stratification • Milestones • Tiered royalties Lilly 2022 Upfront • Research funding • Milestones US$ 180 m per product • Tiered royalties

View entire presentation